EC approves Roche’s Gazyva to treat active lupus nephritis
The decision is based on outcomes from the Phase II NOBILITY and Phase III REGENCY trials.
Drug Development
Inductive Bio gains $21m ARPA-H funds for drug prediction models
Viatris signs agreements with Biocon on $815m stake sale
Agilent and Monash University Malaysia to set up biodiscovery hub
Formosa and Rxilient sign licensing agreement for APP13007
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL
AGC Biologics to expand cell line development with ATUM partnership
Citizen Health and UCB collaborate for epilepsy drug development
